Morningstar

Exact Sciences Corp EXAS

Morningstar Rating
Unlock
Stock XNAS Rating as of
$67.94 +0.17 (0.25%)
View Full Chart
As of Delayed Price Closed

Company Report

View Archive

Exact Sciences Has an Established Colon Cancer Screening Franchise With Progressing Pipeline

Jay Lee

Exact Sciences has a multipronged approach to cancer testing. Current products are Cologuard, its flagship stool-based screening test for colorectal cancer, or CRC, and Oncotype DX, its tissue-based genomic profiling platform with widespread use in breast cancer. It has a promising pipeline in the nascent liquid biopsy market, including a tissue-informed molecular residual disease, or MRD, test, a blood-based CRC screening test, and a multicancer early detection, or MCED, test.

Read Full Report

Price vs Fair Value

View History
EXAS is trading at a 644% premium.
Price
$67.98
Fair Value
$17.00
Uncertainty
Very High
1-Star Price
$178.20
5-Star Price
$79.00
Economic Moat
Wwcsf
Capital Allocation
Qbvvbgqlw

Bulls Say, Bears Say

Bulls

Cologuard’s staying power remains underappreciated, as its superior detection of precancerous lesions compared with liquid biopsies is likely to be viewed favorably by physicians.

Bears

Exact is still at least a couple of years away from profitability, which depends on the speed of Cologuard's sales ramp and the company's ability to realize economies of scale.

Show More

News

View All

Trading Information

Previous Close Price
$67.77
Day Range
$64.85–68.60
52-Week Range
$40.62–79.62
Bid/Ask
$66.00 / $68.90
Market Cap
$12.55 Bil
Volume/Avg
2.8 Mil / 2.7 Mil

Key Statistics

Price/Earnings (Normalized)
718.96
Price/Sales
4.74
Dividend Yield (Trailing)
0.00%
Dividend Yield (Forward)
0.00%
Total Yield
—

Company Profile

Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact’s Cologuard screening test, a noninvasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, or MRD, colorectal cancer screening, and multicancer screening.
Sector
Healthcare
Industry
Diagnostics & Research
Stock Style Box
Mid Growth
Total Number of Employees
0
Website
https://www.exactsciences.com

Competitors

Valuation

View More
Metric
EXAS
ILMN
MYGN
Price/Earnings (Normalized)
 718.96143.77522.41
Price/Book Value
 3.9314.673.22
Price/Sales
 4.744.732.85
Price/Cash Flow
 63.2754.45—
Price/Earnings
EXAS
ILMN
MYGN

Financial Strength

Metric
EXAS
ILMN
MYGN
Quick Ratio
 1.810.741.44
Current Ratio
 2.171.111.96
Interest Coverage
 −7.23−39.58−48.66
Quick Ratio
EXAS
ILMN
MYGN

Profitability

Metric
EXAS
ILMN
MYGN
Return on Assets (Normalized)
 0.13%1.51%0.46%
Return on Equity (Normalized)
 0.26%2.86%0.70%
Return on Invested Capital (Normalized)
 0.43%2.18%0.67%
Return on Assets
EXAS
ILMN
MYGN

Diagnostics & Research Industry Comparables

Screen With Investor
1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Thermo Fisher Scientific Inc
TMO
LlpylctpKbdk$236.6 Bil
 Danaher Corp
DHR
FqwlbdmdbNxmcv$200.0 Bil
 IQVIA Holdings Inc
IQV
ZgyznfbBwtcx$43.1 Bil
 Agilent Technologies Inc
A
XxgwlpjkcBkdtx$42.2 Bil
 IDEXX Laboratories Inc
IDXX
NfwvfhccbMvwd$41.9 Bil
 Mettler-Toledo International Inc
MTD
QjgjxgxysZgcvdf$31.6 Bil
 Icon PLC
ICLR
ZcsklddjsZkykyr$23.7 Bil
 Waters Corp
WAT
HcxmwpmxGxnxc$21.1 Bil
 Illumina Inc
ILMN
JpzschsnThrsrm$21.1 Bil
 Labcorp Holdings Inc
LH
DvlfkqzhlyNpbqndr$18.5 Bil

Sponsor Center